Acrivon Therapeutics
ACRV
18 hedge funds and large institutions have $170M invested in Acrivon Therapeutics in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71.64% more ownership
Funds ownership: 0% → 71.64% (+72%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$61.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$38.2M |
| 3 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
+$21M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$15.5M |
Top Sellers
ACRV Hedge Fund Activity: Q4 2022 in Review
18 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2022, worth a combined $170M.
Buyers outnumbered sellers: 18 funds opened new ACRV positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $61.1M.
- 18 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $170M of Acrivon Therapeutics stock for Q4 2022.
- 18 funds opened new Acrivon Therapeutics positions in Q4 2022 and 0 closed out, a net change of +18 holders.
- The largest Acrivon Therapeutics buyer in Q4 2022 was RA Capital Management, an estimated $61.1M added.
Based on aggregated 13F filings for Q4 2022.